SCHEMBL85319

SCHEMBL85319

CCOC(=O)[C@H]1CC[C@H](OC[C@@H]2C[C@@H](OS(=O)(=O)C(F)(F)F)CN2C)CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 3/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 2/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HTR7 P34969 2/20 0.33
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
GAA P10253 1/20 0.33
ALOX15 P16050 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14772077 0.84 MEN1 (0.36) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL7719279 0.81 KMT2A (0.44) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL84822 0.79 MAPT (0.40) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL85236 0.79 MAPT (0.40) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL10225788 0.79 MAPT (0.40) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL85318 0.78 MAPT (0.35) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL14592498 0.76 TP53 (0.40) NPSR1ALDH1A1HSD17B10MAPTGAA
SCHEMBL30045552 0.76 MEN1 (0.38) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL10225804 0.75 MEN1 (0.38) PKMNPSR1MEN1KMT2AALDH1A1
SCHEMBL85417 0.74 MEN1 (0.37) PKMNPSR1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 PKM 4112/4885NPSR1 1517/4885MEN1 4337/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 PKM 4337/4885NPSR1 2018/4885MEN1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.